| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
October 14, 2026Experienced global healthcare leader to accelerate innovation and expand its impact for laboratories, clinicians and patients. BREA, Calif., Oct. 14, 2026 /PRNewswire/ -- Beckman Coulter...
July 23, 2026The DxU 1800 System features new urine chemistry analyzer and consumables with market-leading microscopy helping laboratories to meet rising diagnostic demand BREA, Calif., July 23, 2026...
July 7, 2026CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline across Europe Brain Derived pTau217 RUO...
-
April 13, 2026
Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April...
September 10, 2025Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in...
March 10, 2025The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical...
January 28, 2025Beckman Coulter Diagnostics, a global leader in clinical diagnostics, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter's...
January 15, 2025New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif., Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in...
September 17, 2024Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term...
July 30, 2024The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brain. These tools have the potential to be used to...
